In a news release, Avivagen Inc. (VIV:TSX.V; VIVXF:OTCQB), which develops and commercializes natural feed products for livestock, companion animal and human applications, announced that the New Zealand Veterinary Journal (NZVJ) has agreed to publish the results from an independent dairy trial focusing on subclinical mastitis.
The firm stated that the published paper is entitled, "Evaluation of fully oxidized β-carotene as a feed ingredient to reduce bacterial infection and somatic cell counts in cows with subclinical mastitis." The company stated that the author, Dr. Scott McDougall, conducted the independent trial in New Zealand and that a preprint of the paper is available for review by anyone interested.
Avivagen noted that about a year ago in February 2020, it reported the positive outcome of the trial to shareholders in a press release.
The company highlighted the two key findings from the trial. The first was that "treatment with OxC-beta™ resulted in a 100% increase in the number of udder-quarters testing negative for the presence of bacteria in milk at the end of the 42-day study." The second notable finding was that "OxC-beta significantly reduced the number of udder-quarters that progressed from subclinical to full clinical mastitis."
The firm noted that the NZVJ, which publishes high quality peer-reviewed articles pertaining to all aspects of veterinary science, ranks among the top 25% of veterinary science journals worldwide. Avivagen advised that the acceptance and publication of the report from the study gives credence to the scientific validity of the benefits of OxC-beta, which is of interest and importance to its customers.
The company commented that it believes publication in the NZVJ will further serve to increase the value of the results with potential clients in global dairy markets. The firm commented that the positive feedback from the trial aided in securing a multi-tonne order of OxC-beta from dairy customers in Mexico.
The company explained that in the dairy industry animals that have been found to be infected with mastitis must be treated with antibiotics. When this happens, the infected cows are removed from milk production until they are completely healthy in order to make sure that their milk does not contain antibiotics. The cost of the antibiotics and caring for the animals combined with the loss of milk production makes mastitis one of the costliest diseases to treat in the dairy industry.
The firm noted that its OxC-beta technology is derived from an overlooked aspect of β-carotene and other carotenoid compound discoveries. Avivagen stated that these compounds are what gives many fruits and vegetables their bright colors and also support immune function, and the OxC-beta technology promotes health and growth and offers immune function support without the use of antibiotics. The company indicated that its proprietary OxC-beta Livestock has demonstrated to be an effective and economical alternative to traditional methods of adding antibiotics to livestock feeds and advised that OxC-beta Livestock is presently available for sale in Australia, Malaysia, New Zealand, the Philippines, Taiwan, Thailand and the U.S.
Avivagen stated that OxC-beta Livestock provides a safe and cost effective means of promoting health and growth and believes the product could serve to fulfill the global mandate to remove all in-feed antibiotics as growth promoters. The company added that numerous international livestock trials with poultry and swine using OxC-beta Livestock have proven that the product performs as well, or better in many cases, than in-feed antibiotics.
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen, a company mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.